Area of research
Pathology and Forensic Medicine · Hematology
Research interest
Research interests include Medicine, Multiple myeloma, Internal medicine, Lymphoma, Immune system, and Transplantation.
Long-Term Survival with Multiple Myeloma: An Italian Experience
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting
A rare complication during autologous stem cell transplantation in multiple myeloma
Infection Events in Patients With Newly Diagnosed Multiple Myeloma With Anti-cd38 Monoclonal Antibody-based First Line Regimens: A Multicentric Italian Experience
A 3D-Printed Tactile Sensor Based on Fiber Bragg Grating Sensors for Lymphadenopathy Detection
Proinflammatory bone marrow niches and neutrophil activation are associated with TIGIT expression in multiple myeloma
Multiparametric Wearable System Based on Fiber Bragg Grating Sensor to Monitor Dengue Clinical Manifestations
A Skin-Attachable Flexible System Based on Fiber Bragg Gratings With Multisite Sensing Capacities for Mother and Fetus Health Monitoring
Sarcopenia Does Not Impact the Outcome of Patients with Multiple Myeloma Consolidated with Autologous Hematopoietic Stem Cell Transplantation
Neuroradiology of acute pathologies in adults with hematologic malignancies: a pictorial review
An innovative multiparametric wearable system for monitoring cardiorespiratory parameters in a pregnant woman and detecting fetal movements
Circulating Endothelial Cell Kinetic in Patients with Multiple Myeloma Who Receive Autologous Hematopoietic Stem Cell Transplantation
Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach
T Cell Ig and ITIM Domains (TIGIT) Expression in Multiple Myeloma
Role of CD68 in the tumor immune microenvironment in Hodgkin’s lymphoma
CLASSICAL HODGKIN DISEASE: PRESENCE OF TIGIT MRNA IN PERITUMORAL LYMPHOCYTES
Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
P23: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY.
Clinical Features and Treatment Response in Patients with Multiple Myeloma and CD20 Expression: Real-Life Experience of the Centro-Italy Multiple Myeloma Macroregional District
A novel scoring system for TIGIT expression in classic Hodgkin lymphoma
MiR‐22, a serum predictor of poor outcome and therapy response in diffuse large B‐cell lymphoma patients
Relapsed/Refractory Multiple Myeloma Patients. a Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy
IgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study
High dose chemotherapy and autologous stem cell transplantation in Multiple Myeloma patients over 70 years: “GIMEMA Working Group Lazio experience
DOAJ (DOAJ: Directory of Open Access Journals) 2020cited by 0position: middle
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)
Gonadal Function Recovery and Fertility in Women Treated with Chemo- and/or Radiotherapy for Hodgkin’s and Non-Hodgkin Lymphoma
May Tigit (T cell Ig and ITIM domain) Expression be a New Target for Hodgkin Lymphoma?
PB2386 BEHAVIOUR OF CIRCULATING ENDOTHELIAL CELLS IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
PD-1 /PD-L1 checkpoint in hematological malignancies
Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients